Berlin -- Bayer Schering Pharma AG, Germany, announced today that an orphan drug designation has been granted by the U.S. Food and Drug Administration (FDA) for the ciprofloxacin dry powder inhaler (DPI) for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in cystic A s

read more>>

South San Francisco, CA -- Cytokinetics, Incorporated (Nasdaq: CYTK) announced today that its fast skeletal muscle troponin activator, CK-2017357, has been granted orphan-drug designation by the U.S. Food and Drug Administration (FDA) for the potential treatment of amyotrophic lateral sclerosis (C

read more>>

LAKE BLUFF, Ill. -- NeoPharm, Inc. (Other OTC: NEOL.PK), announced today that it has filed an orphan drug application with the Office of Orphan Products Development of the United States Food and Drug Administration (FDA) to have Orphan Drug Designation granted to IL13-PE38QQR (IL13-PE) for the The

read more>>

DEAD SEA, Jordan -- Scientists may have uncovered a mechanism for resistance to paclitaxel in ovarian cancer, microRNA-31, suggesting a possible therapeutic target for overcoming chemotherapy resistanceMohamed K. Hassan, Ph.D., a postdoctoral fellow at Hokkaido University in Japan, completed the r

read more>>

Current drugs used to treat heart failure and arrhythmias (irregular heartbeat) have limited effectiveness and have side effectsNew basic science findings from a University of Iowa study suggest a way that treatments could potentially be refined so that they work better and target only key heart-r

read more>>

SILVER SPRING, Md. -- The Coalition for Pulmonary Fibrosis (CPF) and the Pulmonary Fibrosis Foundation (PFF) are applauding the efforts of Pulmonary Fibrosis (PF) patients and family members for their work to convey to the FDA and an FDA Advisory Committee the sense of urgency and desperation Thei

read more>>

ALLSCHWIL/BASEL, SWITZERLAND -- Actelion Ltd (SIX: ATLN) announced today that the company has received a complete response letter from the U.S. Food and Drug Administration (FDA) for its supplemental New Drug Application (sNDA) for Zavesca® (miglustat) for the treatment of progressive The FDA

read more>>

London, UK -- The Board of Ark Therapeutics Group plc ("Ark" or "the Company") today announces an update relating to the Marketing Authorisation Application ("MAA") for its brain cancer treatment, Cerepro®Following a presentation to the EMEA's Scientific Advisory Group on Oncology ("SAG-O") as

read more>>

ABBOTT PARK, Ill., and REDWOOD CITY, Calif. -- Abbott (NYSE: ABT) and Facet Biotech Corporation (Nasdaq: FACT) announced today a definitive agreement for Abbott to acquire Facet, enhancing Abbott's early- and mid-stage pharmaceutical pipelineAbbott will acquire Facet for $27 per share in cash for

read more>>

SEATTLE -- Omeros Corporation (Nasdaq: OMER) today announced that it has obtained an exclusive license to compounds from Asubio Pharma Co., Ltd. for use in its PDE7 program, which is focused on the treatment of movement disordersOmeros has demonstrated a previously unknown link between phosphodies

read more>>